top of page
  • Completed

NCT02252263: Phase 1: Elotuzumab (BMS-901608) With Lirilumab (BMS-986015) or Urelumab (BMS-663513)

NCT02252263: Phase 1: A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma


Elotuzumab (BMS-901608) With Lirilumab (BMS-986015) or Urelumab (BMS-663513)

A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma


To assess the safety and tolerability, characterize the dose limiting toxicities (DLTs) and identify the maximally tolerated dose (MTD) of Elotuzumab administered in combination with either Lirilumab or Urelumab in subjects with multiple myeloma.



Sponsor

Bristol-Myers Squibb

 

ClinicalTrials.gov Identifier: NCT02252263

Official Title: A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

First Posted : September 30, 2014

Click here for details on ClinicalTrials.gov

 

Elotuzumab

Elotuzumab (Code C66982)

BMS-901608

Elotuzumab

ELOTUZUMAB

Empliciti

HuLuc-63

HuLuc63

PDL-063